TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

6A.6 Del Rosso JQ et al. A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris. Cutis 2010;85:15-24. 6A.7 Schöfer H et al. Fusidic acid in dermatology: an updated review. Eur J Dermatol 2010;20:6-15. 6A.8 Korting HC et al. Current topical and systemic approaches to treatment of rosacea. J Eur Acad Dermatol Venereol 2009;23:876-82. 6A.9 Patel JB et al. Mupirocin resistance. Clin Infect Dis 2009;49:935-41. 6A.10 European Medeines Agency (EMA). European assessment report (EPAR). Altargo TM , summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR _-_Product_Information/human/000757/WC500024409.pdf. Accessed on August 4th 2010. 6A.11 Scangarella-Oman NE et al. Microbiological profile of a new topical antibacterial: retapamulin ointment 1%. Expert Rev Anti Infect Ther 2009;7:269-79. 6A.12 Woodford N et al. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother 2008;62:766-8. 6C.1 Liesegang TJ. Bacterial keratitis. Infect Dis Clin North Am 1992;6:815-29. 7.1 Nucci M et al. Emerging fungi. Infect Dis Clin North Am 2006;20:563-79. 7.2 Nucci M et al. Emerging fungal diseases. Clin Infect Dis 2005;41:521-6. 7.3 Pfaller MA et al. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006;43 (suppl. 1):S3-14. 7.4 De Pauw B et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21. 7.5 Alexander BD et al. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis 2006;43(suppl. 1):S15-27. 7.6 Lass-Flörl C. Invasive fungal infections in pediatric patients: a review focusing on antifungal therapy. Expert Rev Anti Infect Ther 2010;8:127-35. 7.7 Mukherjee PK et al. Combination treatment of invasive fungal infections. Clin Microbiol Rev 2005; 18:163-94. 7.8 Nivoix Y et al. Combination of caspofungin and an azole or an amphotericin B formulation in invasive fungal infections. J Infect 2006;52:67-74. 7.9 Bille J et al. Changing face of health care associated fungal infections. Curr Opin Infect Dis 2005; 18:314-9. 7.10 Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents. Morb Mortal Wkly Rep 2009;58(RR-4):1- 207. 7.11 Centers for Disease Control and Prevention (CDC). Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children. Morb Mortal Wkly Rep 2009; 58(RR-11):1-167. 7.12 Revankar SG. Therapy for infections caused by dematiaceous fungi. Expert Rev Anti Infect Ther 2005;3:601-12. 7.13 Nucci M et al. When primary antifungal therapy fails. Clin Infect Dis 2008;46:1426-33. 7.14 Cordonnier C et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009;48:1042-51. 7.15 de Pauw BE et al. Timely intervention for invasive fungal disease: should the road now lead to the laboratory instead of the pharmacy? Clin Infect Dis 2009;48:1052-4. 7.16 Segal BH. Aspergillosis. N Engl J Med 2009;360:1870-84. 7.17 Singh N et al. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005;18:44-69. 7.18 Barnes PD et al. Aspergillosis: spectrum of disease, diagnosis, and treatment. Infect Dis Clin North Am 2006;20:545-61. 7.19 Walsh TJ et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. 7.20 Pasqualotto AC et al. Post-operative aspergillosis. Clin Microbiol Infect 2006;12:1060-76. 7.21 Hassoun A. Cauliflower mass obstructing the left main-stem bronchus. Clin Infect Dis 2008;47:585- 6. 7.22 Gibson PG. Allergic bronchopulmonary aspergillosis. Semin Respir Crit Care Med 2006;27:185-91. 7.23 Shoseyov D et al. Aspergillus bronchitis in cystic fibrosis. Chest 2006;130:222-6. 7.24 Tillie-Leblond I et al. Allergic bronchopulmonary aspergillosis. Allergy 2005;60:1004-13. 7.25 Stevens DA et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis. State of the art: Cystic Fibrosis Foundation consensus conference. Clin Infect Dis 2003;37(suppl. 3):S225-64. 7.26 Stevens DA et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000;342:756-62. 7.27 Marple BF. Allergic fungal rhinosinusitis: current theories and management strategies. Laryngoscope 2001;111:1006-19. 7.28 Sohail MA et al. Allergic fungal sinusistis: can we predict the recurrence? Otolaryngol Head Neck Surg 2004;131:704-10. 7.29 Ebbens FA et al. Amphotericin B nasal lavages: not a solution for patients with chronic rhinosinusitis. J Allergy Clin Immunol 2006;118:1149-56. 7.30 Kim YT et al. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005;79:294-8. 7.31 Okubo K et al. Favorable acute and long-term outcomes after the resection of pulmonary aspergillomas. Thorac Cardiovasc Surg 2007;55:108-11. 7.32 Chatzimichalis A et al. Bronchopulmonary aspergilloma: a reappraisal. Ann Thorac Surg 1998;65: 927-9. 7.33 Maertens J et al. New therapies for fungal pneumonia. Curr Opin Infect Dis 2009;22:183-90. 7.34 Segal BH et al. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006;173:707-17. 7.35 Doffman SR et al. Invasive pulmonary aspergillosis. Expert Rev Anti Infect Ther 2005;3:613-27. 7.36 Ruhncke M et al. CNS aspergillosis: recognition, diagnosis and management. CNS Drugs 2007;21: 659-76. 7.37 Ader F et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect 2005;11:427-9.
7.38 Meersseman W et al. Invasive aspergillosis in the intensive care unit. Clin Infect Dis 2007;45:205- 16. 7.39 Upton A et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531-40. 7.40 Maertens J et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009;49:1688-93. 7.41 Miceli MH et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications. Clin Infect Dis 2008;46:1412-22. 7.42 Deasi R et al. The role of bronchoalveolar lavage galactomannan in the diagnosis of pediatric invasive aspergillosis. Pediatr Infect Dis J 2009;28:283-6. 7.43 Meersseman W et al. Galactomannan in bronchoalveolar lavage fluid. A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med 2008;177:27-34. 7.44 Hope WW et al. Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis 2005;5:609-22. 7.45 Pfeiffer CD et al. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006;42:1417-27. 7.46 Marr KA et al. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immuno-assay. Clin Infect Dis 2005;40:1762-9. 7.47 Greene RE et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9. 7.48 Vandewoude KH et al. Medical imaging and timely diagnosis of invasive pulmonary aspergillosis. Clin Infect Dis 2007;44:380-1. 7.49 Dockrell DH. Salvage therapy for invasive aspergillosis. J Antimicrob Chemother 2008;61(suppl. 1): i41-4. 7.50 Burgos A et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008;121:e1286-94. 7.51 Maschmeyer G et al. Invasive aspergillosis. Epidemiology, diagnosis, and management in immunocompromised patients. Drugs 2007;67:1567-1601. 7.52 Cornillet A et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6-year survey. Clin Infect Dis 2006;43;577-84. 7.53 Muñoz P et al. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006;12(suppl. 7):24-39. 7.54 Segal BH et al. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006;173:707-17. 7.55 Steinbach WJ. Pediatric aspergillosis. Disease and treatment differences in children. Pediatr Infect Dis J 2005;24:358-64. 7.56 Chandrasekar PH et al. Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2005;40(suppl. 6):S392-400. 7.57 Mouas H et al. Voriconazole for invasive bone aspergillosis: a worldwide experience of 20 cases. Clin Infect Dis 2005;40:1141-7. 7.58 Zaoutis TE et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics 2009;123:877-94. 7.59 Herbrecht R et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15. 7.60 Sambatakou H et al. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis. Am J Med 2006;119:527.e17-24. 7.61 Steinbach WJ et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004;39:192-8. 7.62 Cornely OA et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high loading-dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-97. 7.63 Anaissie AJ. Trial design for mold-active agents: time to break the mold – aspergillosis in neutropenic adults. Clin Infect Dis 2007;44:1298-306. 7.64 van der Linden JW et al. Azole-resistant central nervous system aspergillosis. Clin Infect Dis 2009; 48:1111-3. 7.65 Maertens J et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004;39:1563-71. 7.66 Singh N et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational trial. Transplantation 2006;81:320-6. 7.67 Petraitis V et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003;187:1834-43. 7.68 Walsh TJ et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12. 7.69 Miceli MH et al. Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: proof of principle, description, and clinical and research implications. Cancer 2007;110:112-20. 7.70 Viscoli C. Combination therapy for invasive aspergillosis. Clin Infect Dis 2004;39:803-5. 7.71 Pascual A et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. 7.72 Lewis JS. Therapeutic drug monitoring of antifungal agents. Curr Fungal Infect Rep 2009;3:96-102. 7.73 Trifilio S et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. 7.74 Saccente M et al. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 2010;23:367- 81. 7.75 Bariola JR et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern area. Clin Infect Dis 2010;50:797-804. 7.76 Kauffman CA. Endemic mycoses: blastomycosis, histoplasmosis, and sporotrichosis. Infect Dis Clin North Am 2006;20:645-62. 7.77 Chapman SW et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis 2008;46:1801-12. 7.78 Bradsher RW et al. Blastomycosis. Infect Dis Clin North Am 2003;17:21-40. 7.79 Trofa D et al. Candida parapsilosis, an emerging fungal pathogen. Clin Microbiol Rev 2008;21:606-
Page 1 and 2: TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4: 1.89 Laupland KB. Vascular and para
Page 5 and 6: of NICE guidance. Br Med J 2008;337
Page 7 and 8: tions à Clostridium difficile dans
Page 9 and 10: sis of placebo-controlled trials. C
Page 11 and 12: 1.446 Centers for Disease Control a
Page 13 and 14: 1.532 Olaison L et al. Enterococcal
Page 15 and 16: 1.615 Muder RR et al. Isolation of
Page 17 and 18: 2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20: 2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22: 1.873 Korting HC et al. Current top
Page 23 and 24: 1.970 Thomas RJ et al. Current mana
Page 25 and 26: of severe respiratory failure. Clin
Page 27 and 28: 1.1166 Aldape MJ et al. Clostridium
Page 29 and 30: 2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32: test methodology. Eur J Clin Microb
Page 33 and 34: 2B.39 Cookson BD et al. Guidelines
Page 35 and 36: 2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38: 82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40: after acute pyelonephritis: a multi
Page 41 and 42: for intensive care patients with no
Page 43 and 44: among hospitalized patients. Clin I
Page 45: Ther 2006;4:947-52. 5D.1 Demirovic
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98:
product characteristics. Available
Page 99 and 100:
mortality after kidney transplantat
Page 101 and 102:
33A.1 Kearney BP et al. The penetra
Page 103 and 104:
Clin Plast Surg Clinics in Plastic
Page 105 and 106:
Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

Create successful ePaper yourself

Delete template?

Save as template?